Inventor · disambiguated record
David P. Bingaman
Also filed as: BINGAMAN DAVID P
15 granted patents·65 pending applications·52 citations·filing 2001–2024
91Inventor score
Top patents by PatentIndex Score
80 records- 0197US8940887B2RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesisALCON RES LTD·Filed 2013·Granted Jan 27, 2015·31 cites·2 claims
- 0288US9446026B2Ocular formulations for drug-delivery to the posterior segment of the eyePANOPTICA INC·Filed 2014·Granted Sep 20, 2016·8 cites·11 claims
- 0387US10183014B2Ocular formulations for drug-delivery and protection of the anterior segment of the eyePANOPTICA INC·Filed 2017·Granted Jan 22, 2019·2 cites·21 claims
- 0487US9814702B2Ocular formulations for drug-delivery and protection of the anterior segment of the eyePANOPTICA INC·Filed 2015·Granted Nov 14, 2017·2 cites·18 claims
- 0587US9623011B2Ocular formulations for drug-delivery and protection of the anterior segment of the eyePANOPTICA INC·Filed 2016·Granted Apr 18, 2017·2 cites·12 claims
- 0687US2024325357A1Ocular formulations for drug-delivery to the posterior segment of the eyePANOPTICA INC·Filed 2024·Application pending·0 cites
- 0785US2024277674A1Ocular formulations for drug-delivery and protection of the anterior segment of the eyePANOPTICA INC·Filed 2023·Application pending·0 cites
- 0885US2022364097A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0983US10307404B1Ocular formulations for drug-delivery to the posterior segment of the eyePANOPTICA INC·Filed 2018·Granted Jun 4, 2019·2 cites·37 claims
- 1083US2022162614A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1182US2022042021A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1281US7981870B2RNAi-mediated inhibition of H1F1A for treatment of ocular angiogenesisALCON RES LTD·Filed 2010·Granted Jul 19, 2011·2 cites·12 claims
- 1379US2021230603A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1479US2021108206A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1578US10092549B2Ocular formulations for drug-delivery to the posterior segment of the eyePANOPTICA INC·Filed 2014·Granted Oct 9, 2018·2 cites·20 claims
- 1678US2020392508A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1777US2020277608A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1876US2020165615A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1975US2019338287A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2075US2020048637A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2174US2021196690A1Ocular formulations for drug-delivery to the posterior segment of the eyePANOPTICA INC·Filed 2021·Application pending·0 cites
- 2274US2019256854A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2373US2019144866A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2473US2019071676A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2572US2021275501A1Ocular formulations for drug-delivery and protection of the anterior segment of the eyePANOPTICA INC·Filed 2020·Application pending·0 cites
- 2671US2015167002A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISALCON RES LTD·Filed 2014·Application pending·0 cites
- 2768US2017198294A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 2867US2019247368A1Ocular formulations for drug-delivery to the posterior segment of the eyePANOPTICA INC·Filed 2019·Application pending·0 cites
- 2967US2019240201A1Ocular formulations for drug-delivery to the posterior segment of the eyePANOPTICA INC·Filed 2019·Application pending·0 cites
- 3066US9139834B2RNAi-related inhibition of TNF alpha signaling pathway for treatment of ocular angiogenesisARROWHEAD RES CORP·Filed 2014·Granted Sep 22, 2015·0 cites·17 claims
- 3166US8471000B2RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesisCHATTERTON JON E·Filed 2012·Granted Jun 25, 2013·0 cites·1 claims
- 3266US2009036397A1RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMAALCON RES LTD·Filed 2008·Application pending·0 cites
- 3366US2009036396A1RNAi-RELATED INHIBITION OF TNFalpha SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESISALCON RES LTD·Filed 2008·Application pending·0 cites
- 3466US2007155690A1RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesisALCON MFG LTD·Filed 2006·Application pending·0 cites
- 3565US2010048608A1Histone Deacetylase Inhibitors for the Treatment of Ocular Neovascular or Edematous Disorders and DiseasesALCON INC·Filed 2009·Application pending·0 cites
- 3665US2019314343A1Ocular formulations for drug-delivery and protection of the anterior segment of the eyePANOPTICA INC·Filed 2018·Application pending·0 cites
- 3763US2011257246A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISALCON RES LTD·Filed 2011·Application pending·0 cites
- 3861US2009035225A1RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMAALCON RES LTD·Filed 2008·Application pending·0 cites
- 3960US9422556B2RNAi-related inhibition of TNF-alpha signaling pathway for treatment of ocular angiogenesisARROWHEAD RES CORP·Filed 2015·Granted Aug 23, 2016·0 cites·16 claims
- 4060US8754202B2RNAi-related inhibition of TNFα signaling pathway for treatment of ocular angiogenesisCHATTERTON JON E·Filed 2011·Granted Jun 17, 2014·0 cites·1 claims
- 4160US2016354349A1Ocular formulations for drug-delivery to the posterior segment of the eyePANOPTICA INC·Filed 2016·Application pending·0 cites
- 4260US2016326533A1RNAi-Related Inhibition of TNF-alpha Signaling Pathway for Treatment of Ocular AngiogenesisARROWHEAD PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 4359US2009181933A1Use of steroids to treat persons suffering from ocular disordersBINGAMAN DAVID P·Filed 2008·Application pending·0 cites
- 4458US8722015B2Compositions and methods for treatment of angiogenesis-associated ocular disordersKAZLAUSKAS ANDRIUS·Filed 2011·Granted May 13, 2014·1 cites·6 claims
- 4558US7879905B25,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responsesALCON INC·Filed 2005·Granted Feb 1, 2011·0 cites·1 claims
- 4658US2009105245A1Methods for treating macular edema and ocular angiogenesis using an anti-inflammatory agent and a receptor tyrosine kinase inhibitorBINGAMAN DAVID P·Filed 2007·Application pending·0 cites
- 4757US2011190376A1RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMAALCON RES LTD·Filed 2011·Application pending·0 cites
- 4857US2015057336A1RNAi-RELATED INHIBITION OF TNF alpha SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMAALCON RES LTD·Filed 2014·Application pending·0 cites
- 4955US2010267811A1RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESISALCON RES LTD·Filed 2010·Application pending·0 cites
- 5054US2007275922A1RNAi-MEDIATED INHIBITION OF IGF1R FOR TREATMENT OF OCULAR ANGIOGENESISALCON MFG LTD·Filed 2006·Application pending·0 cites
Showing the top 50 of 80 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when David P. Bingaman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →